Cellular Responses to p53 Activation by Nutlin-3a
Nutlin-3a 激活 p53 的细胞反应
基本信息
- 批准号:7735485
- 负责人:
- 金额:$ 31.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-13 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:ActinsAdverse effectsAneuploid CellsAneuploidyApoptosisAutomobile DrivingBiological AssayBreast Cancer CellCancer cell lineCell LineCellsChromosomesCisplatinCollectionCytoskeletal ModelingDNADNA DamageDNA biosynthesisDataDevelopmentDoseEpithelial CellsExcisionFamilyFocal AdhesionsG1 ArrestGenerationsGenomic InstabilityGlucocorticoid ReceptorGoalsGrantGrowthGuanosine Triphosphate PhosphohydrolasesHCT116 CellsHumanInvadedM cellMDM2 geneMYC geneMalignant NeoplasmsMammary glandMediatingMitosisNormal CellPathway interactionsPharmaceutical PreparationsPolyploid CellsProtein p53RU-486RadiationReceptor ActivationReportingResistanceSignal TransductionStressStress FibersTP53 geneTestingTherapeuticTherapeutic AgentsTissuesTumor Suppressor Proteinsanticancer researchbasecancer cellcancer therapycarcinogenesiscell growthcell motilitycell typeimmortalized cellin vivointerestkillingsmatrigelmigrationnutlin 3preventpublic health relevanceresponserhosmall moleculewound
项目摘要
DESCRIPTION (provided by applicant): Wild-type p53 is a potent tumor suppressor that is activated by DNA damage and other stresses. There has been considerable interest in restoring wild-type p53 function as a therapeutic strategy. This goal has led to the development of the Nutlin-3 (Nutlin), a small molecule that activates wild-type p53 by blocking its interaction with MDM2, the primary negative regulator of p53 activity in cells. Notably, Nutlin activates p53 through a non-genotoxic mechanism, and thus its use as a therapeutic agent may spare tissues of deleterious side-effects associated with common DNA damaging drugs. Effective use of Nutlin requires that its effects on cells be fully understood. We have examined the response of various p53 wild-type cell lines to transient Nutlin treatment. We find that p53 activation by Nutlin can promote growth arrest or apoptosis in cells dependent on activation of survival pathways, and we have identified a candidate survival factor that protects cells from Nutlin-induced apoptosis. We also find that Nutlin has surprising effects on cytoskeletal organization and control of DNA endoreduplication. The purpose of this grant is to determine the effects of Nutlin-mediated p53 activation on these various cellular responses.
PUBLIC HEALTH RELEVANCE: Project Narrative: Cell growth can be considered similar to driving a car; there are accelerators that increase cell growth and brakes that prevent cells from growing too fast. The p53 protein is an important cell brake that prevents normal cells from becoming cancer, and p53 is inactive in most human cancers. We are studying the effects of p53 activation by Nutlin-3a, a small molecule that specifically activates wild-type p53 in a subset of cancers.
描述(由申请人提供):野生型p53是一种有效的肿瘤抑制因子,可被DNA损伤和其他应激激活。恢复野生型p53功能作为一种治疗策略已经引起了相当大的兴趣。这一目标导致了Nutlin-3(Nutlin)的开发,Nutlin-3是一种通过阻断野生型p53与MDM 2(细胞中p53活性的主要负调节因子)的相互作用来激活野生型p53的小分子。值得注意的是,Nutlin通过非遗传毒性机制激活p53,因此其作为治疗剂的用途可以使组织免于与常见DNA损伤药物相关的有害副作用。有效使用Nutlin需要充分了解其对细胞的影响。我们已经研究了各种p53野生型细胞系对瞬时Nutlin治疗的反应。我们发现Nutlin激活p53可以促进依赖于生存途径激活的细胞生长停滞或凋亡,并且我们已经确定了一种保护细胞免受Nutlin诱导的凋亡的候选生存因子。我们还发现Nutlin对细胞骨架组织和DNA内复制的控制具有令人惊讶的作用。这项研究的目的是确定Nutlin介导的p53激活对这些不同细胞反应的影响。
公共卫生相关性:项目叙述:细胞生长可以被认为类似于驾驶汽车;有加速器可以加速细胞生长,刹车可以防止细胞生长过快。p53蛋白是一种重要的细胞制动器,可以防止正常细胞变成癌症,而p53在大多数人类癌症中是无活性的。我们正在研究Nutlin-3a对p53激活的影响,Nutlin-3a是一种小分子,可以特异性激活癌症亚组中的野生型p53。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Carl G Maki其他文献
Carl G Maki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Carl G Maki', 18)}}的其他基金
A synthetic lethal approach for targeting p53 deficient triple negative breast cancer
针对 p53 缺陷三阴性乳腺癌的合成致死方法
- 批准号:
10650026 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
- 批准号:
9461165 - 财政年份:2017
- 资助金额:
$ 31.13万 - 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
- 批准号:
9115348 - 财政年份:2016
- 资助金额:
$ 31.13万 - 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
- 批准号:
9253372 - 财政年份:2016
- 资助金额:
$ 31.13万 - 项目类别:
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
靶向脯氨酰肽酶治疗他莫昔芬耐药乳腺癌
- 批准号:
9912119 - 财政年份:2016
- 资助金额:
$ 31.13万 - 项目类别:
Identification and Targeting Therapy Resistant Osteosarcoma
骨肉瘤耐药性的识别和靶向治疗
- 批准号:
8814732 - 财政年份:2015
- 资助金额:
$ 31.13万 - 项目类别:
Modeling The Etiology of P53 Mutated Cancer Cells
P53 突变癌细胞的病因学建模
- 批准号:
8571884 - 财政年份:2013
- 资助金额:
$ 31.13万 - 项目类别:
Modeling The Etiology of P53 Mutated Cancer Cells
P53 突变癌细胞的病因学建模
- 批准号:
8704904 - 财政年份:2013
- 资助金额:
$ 31.13万 - 项目类别:
Cellular Responses to p53 Activation by Nutlin-3a
Nutlin-3a 激活 p53 的细胞反应
- 批准号:
8471662 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别:
Cellular Responses to p53 Activation by Nutlin-3a
Nutlin-3a 激活 p53 的细胞反应
- 批准号:
8271293 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 31.13万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 31.13万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 31.13万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 31.13万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 31.13万 - 项目类别:
Studentship